Envista Holdings (NVST) has tightened the link between its leadership and board, with President and CEO Paul Keel appointed Chair, while former Chair Scott Huennekens shifts to Lead Independent Director effective August 19, 2026.

Envista Holdings’ recent board changes come as the stock trades at US$26.93, with the share price up 14.94% over 90 days and the 1-year total shareholder return at 31.62%, while the 5-year total shareholder return remains down 34.95%.

If this kind of leadership reset has you thinking about where else growth stories might emerge, it could be a good moment to widen your search with the 41 healthcare AI stocks

Envista Holdings trades at a discount to both analyst targets and an estimated intrinsic value, even after the recent rebound. Is that a sign of opportunity, or is the market still cautious for good reason?

Most Popular Narrative: 9.3% Undervalued

Envista Holdings is priced at $26.93 against a most-followed narrative fair value of $29.69, with that view built on specific growth and margin assumptions discounted at 8.2%.

Increasing R&D investment (up 14% year-over-year) and successful launches of digital and AI-driven products (e.g., DTX Studio Clinic with AI, DEXIS CDCTs, Spark product line) enhance Envista's ability to capitalize on growing demand for digital dentistry, supporting both future revenue growth and gross margin expansion.

Want to understand why this Envista Holdings narrative supports a higher fair value than today’s price? The core of the story is measured revenue gains, rising margins and a future earnings multiple that assumes meaningful execution on digital dentistry and recurring revenue. Curious which exact growth and profitability paths have been baked into that $29.69 figure.

Result: Fair Value of $29.69 (UNDERVALUED)

However, Envista Holdings still faces pressure from China volume based procurement and tariff related costs. These factors could limit margins if these headwinds persist or intensify.

Another View on Envista Holdings Valuation

The narrative model suggests Envista Holdings is undervalued, yet the current P/E of 45.5x tells a different story. That multiple is above the US Medical Equipment industry at 28x, the peer average at 31.5x, and the fair ratio of 32.6x, which the market could move toward over time. This premium may indicate either confidence in the earnings story or additional valuation risk if sentiment cools.

Next Steps

If the Envista Holdings story so far sounds promising but incomplete, this is the moment to check the details yourself and act while sentiment is taking shape. To see what is driving current optimism, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond Envista Holdings?

Envista Holdings may be on your radar, but you do not want to miss other stocks that could suit your goals just as well or even better.

• Spot potential value opportunities early by reviewing the 50 high quality undervalued stocks before they attract wider attention.
• Strengthen your focus on resilience by filtering companies through the 79 resilient stocks with low risk scores that aim for steadier profiles.
• Hunt for under-followed opportunities by scanning the screener containing 19 high quality undiscovered gems that many investors may still be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.